Devices and methods for treatment of vascular aneurysms

Information

  • Patent Grant
  • 10470868
  • Patent Number
    10,470,868
  • Date Filed
    Thursday, January 7, 2016
    8 years ago
  • Date Issued
    Tuesday, November 12, 2019
    4 years ago
  • Inventors
  • Original Assignees
    • (Mountain View, CA, US)
  • Examiners
    • Severson; Ryan J.
    Agents
    • Levine Bagade Han LLP
Abstract
The present invention relates to devices and methods for the treatment of diseases in the vasculature, and more specifically, devices and methods for treatment of aneurysms found in blood vessels. In a first embodiment of the present invention, a two part prostheses, where one part is an expandable sponge structure and the other part is an expandable tubular mesh structure, is provided. In the first embodiment, the expandable sponge structure is intended to fill the aneurysm cavity to prevent further dilatation of the vessel wall by creating a buffer or barrier between the pressurized pulsating blood flow and the thinning vessel wall. In the first embodiment, the expandable tubular mesh structure is placed across the aneurysm, contacting the inner wall of healthy vessel proximal and distal to the aneurysm.
Description
BACKGROUND OF THE INVENTION

The present invention relates to devices and methods for the treatment of diseases in the vasculature, and more specifically, devices and methods for treatment of aneurysms found in blood vessels. Aneurysms can occur in various areas of the cardiovascular system, but are commonly found in the abdominal aorta, thoracic aorta, and cerebral vessels. Aneurysms are unusual ballooning of the vessel due to loss of strength and/or elasticity of the vessel wall. With the constant pulsating pressure exerted on the vessel wall, the diseased or weakened wall can expand out and potentially rupture, which frequently leads to fatality. Prior methods of treating aneurysms have consisted of invasive surgical techniques. The technique involves a major cut down to access the vessel, and the diseased portion of the vessel is replaced by a synthetic tubular graft. Accordingly, this invasive surgical procedure has high mortality and morbidity rates.


Due to the inherent risks and complexities of the surgical procedures, various attempts have been made to develop minimally invasive methods to treat these aneurysms. For treatment of abdominal and thoracic aortic aneurysms, most of the attempts are catheter-based delivery of an endoluminal synthetic graft with some metallic structural member integrated into the graft, commonly called stent-grafts. One of the primary deficiencies of these systems is durability of these implants. Because catheter-based delivery creates limitations on size and structure of the implant that you can deliver to the target site, very thin synthetic grafts are in attached to metallic structures, where constant interaction between the two with every heartbeat can cause wear on the graft. Also, the metallic structures often see significant cyclical loads from the pulsating blood, which can lead to fatigue failure of the metallic structure. The combination of a thin fragile graft with a metallic structure without infinite life capabilities can lead to implant failure and can ultimately lead to a fatality.


While the above methods have shown some promise with regard to treating aortic aneurysms with minimally invasive techniques, there remains a need for a treatment system which doesn't rely on the less than optimal combination of a thin graft and metallic structural member to provide long-term positive results. The present invention describes various embodiments and methods to address the shortcomings of current minimally invasive devices and to meet clinical needs.


SUMMARY OF THE INVENTION

In a first aspect, the present invention provides a two part prostheses where one part is an expandable sponge structure and the other part is an expandable tubular mesh structure. The expandable sponge structure is intended to fill the aneurysm cavity to prevent further dilatation of the vessel wall by creating a buffer or barrier between the pressurized pulsating blood flow and the thinning vessel wall. The expandable tubular mesh structure, which is placed across the aneurysm contacting the inner wall of healthy vessel proximal and distal the aneurysm, serves two purposes. One, it defines the newly formed vessel lumen, even though it does not by itself provide a fluid barrier between the blood flow and the aneurysm. Two, it keeps the expandable sponge structure from protruding out of the aneurysm and into the newly formed vessel lumen. The expandable tubular mesh structure is delivered first across the aneurysm. Then, the expandable sponge structure is delivered via a catheter-based delivery system through a “cell” of the tubular mesh structure and into the aneurysm sac. When the sponge structure is deployed into the aneurysm sac and comes in contact with fluid, it will expand to a size larger than the largest opening or cell of the tubular mesh structure as to prevent the sponge structure from getting out of the aneurysm sac. The filled aneurysm sac will most likely clot off and prevent further dilation of the aneurysm and subsequent rupture. The blood flow should maintain a natural lumen where the luminal diameter is approximately defined by the diameter of the tubular mesh structure. The advantage of this system is that the sponge filler material acts like a graft but has unparalleled durability. The metallic structure can be optimized for durability as well because the size constraint is somewhat relieved due to the absence of an integrated graft material, which takes up a significant amount of space in a catheter.


In addition, the expandable sponge structure can be used to repair existing endoluminal stent-grafts which have developed leaks. There are thousands of endoluminal stent-grafts implanted into humans to treat abdominal aortic aneurysms. That number is growing daily. The endoluminal stent-grafts are intended to exclude the aneurysm from blood flow and blood pressure by placing a minimally porous graft supported fully or partially by metallic structural members, typically called stents. The acute success rate of these devices is very high, but there are a significant number of these which develop leaks, or blood flow/pressure re-entering the aneurysm sac, some time after the procedure. If the source of the leak can be accessed by the delivery system, the expandable sponge structure can be deployed through that access point.


In another aspect, the present invention provides an inflatable tubular balloon graft. It is a tubular graft, straight or bifurcated, where its wall is not a solid structure but a hollow chamber. The chamber can be filled with a variety of materials which can dictate the mechanical properties of the prostheses. The unfilled tubular balloon graft can be folded and loaded into a catheter-based delivery system, and once in position the tubular balloon graft can be “inflated” with the filler material. The material would be filled in a fluid form and may stay a fluid form or can be solidified by various means such as UV light, heat, and time. The advantage of this system is that a metallic structure is not needed to provide structure to the graft. It is instead replaced by the injectable fluid within the chamber of the tubular balloon graft. Customization of the mechanical properties of the graft is easily accomplished by using balloon fillers of varying properties.


The tubular balloon graft can be completely non-porous, completely porous with same degree of porosity throughout the graft, completely porous with varying porosity within the graft, or partially non-porous and partially porous. Significant porosity on the very outer layer would allow for delivery of an aneurysm sac filling substance or a drug. Porosity on the ends of the graft will help promote cellular in-growth. Porosity on the ends can also be used to deliver an adhesive so that the graft can be securely attached to the vessel wall.


Another embodiment of the tubular balloon graft includes a tubular balloon graft with a bulging outer layer. This will allow the outer surface of the tubular balloon graft to fill some or all of the aneurysm. This will provide a primary or secondary barrier for the aneurysm wall from the pulsating blood flow and will provide a means to prevent migration of the graft due to the enlarged area within the graft. An alternate method of construction would be to attach a bulging outer skin to a standard tubular thin-walled graft and provide a port for injection of the filler substance. Alternatively, instead of a bulging outer skin, a very compliant outer skin can be used so that the volume of material is minimized. The compliant outer skin would be able to expand at very low inflation pressures that would be non-destructive to the aneurysm wall.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1A illustrates the two-part prosthesis.



FIG. 1B illustrates a bifurcated version of the expandable tubular mesh structure and the expandable sponge structure.



FIG. 1C illustrates an expandable tubular mesh structure placed across an aneurysm and the expandable sponge structure filling up the aneurysm.



FIGS. 2A-2C illustrate the various cross-sections of the expandable sponge structure.



FIG. 3A illustrates a long continuous sponge structure.



FIG. 3B illustrates multiple short sponge structures.



FIG. 4 illustrates the catheter-based delivery system.



FIG. 5 illustrates a curved delivery catheter.



FIG. 6 illustrates a method of ensuring that the delivery catheter's tip stays inside the aneurysm sac.



FIG. 7A illustrates an expandable basket-like structure.



FIG. 7B illustrates an expandable braid-like structure.



FIGS. 8 and 9 illustrate expandable tubular mesh structures.



FIG. 10 illustrates a delivery catheter tracked over a guidewire and placed in a stent-graft which developed a leak.



FIG. 11 illustrates the sponge delivered through the delivery catheter.



FIGS. 12-15 illustrate tubular balloon grafts.



FIGS. 16 and 17 illustrate tubular balloon grafts being expanded.



FIG. 18 illustrates a tubular balloon graft.



FIGS. 19, 20A and 20 B illustrate a vascular graft with an integrated tubular balloon.



FIGS. 21A-21E illustrate a method of delivering a graft with an external balloon.





DETAILED DESCRIPTION OF THE INVENTION


FIG. 1A shows the two-part prosthesis comprising of an expandable sponge structure 1 and an expandable tubular mesh structure 2 placed in an abdominal aortic aneurysm 3 located in the infra-renal aorta not involving the iliac arteries. FIG. 1B shows a bifurcated version of the expandable tubular mesh structure 2 and the expandable sponge structure 1 in an abdominal aortic aneurysm located in the infra-renal aorta and involving, both iliac arteries. FIG. 1C shows an expandable tubular mesh structure 2 placed across an aneurysm commonly found in cerebral arteries and the expandable sponge structure 1 filling up the aneurysm. The expandable sponge structure 1 is placed through the expandable tubular mesh structure 2 into the aneurysm, filling up the aneurysmal sac which provides a barrier between the thin fragile wall of the aneurysm and the pressurized pulsating blood. The tubular mesh structure 2 keeps the expanded sponge 1 within the confines of the aneurysm and away from the flow path.


The expandable sponge structure 1 is preferably made of common medical grade polymers or natural substances like collagen which can be manufactured into a sponge structure. The sponge structure can be processed in such a way so that it can be compressed to a dry condition size substantially smaller than the wet condition size, exhibiting huge expansion ratio. The expanded sponge structure can take various forms. FIGS. 2A-2C show the various expanded cross-sections that the expandable sponge structure 1 can be. FIG. 2A shows a circular cross section. FIG. 2B shows a square cross section, and FIG. 2C show a triangular cross section. Any cross section can be used. The most important requirement is that it cannot escape from the aneurysm sac through a cell of the expandable tubular mesh structure 2. The length of the expandable sponge structure 1 can vary as well. FIG. 3A shows a long continuous structure 1. And FIG. 3B shows multiple short structures 1.


One method of delivering the sponge filler 1 into the aneurysm sac is shown by the catheter-based delivery system in FIG. 4. The catheter 4 can hold the compressed sponge 1 within its lumen, and when pushed out with the plunger 5 into the blood filled aneurysm sac, the sponge will expand out to a substantially larger size. The expanded size of the sponge filler is preferably larger than the largest opening of the tubular mesh structure as to prevent the sponge from escaping the aneurysm sac. FIG. 5 shows an example of a curved delivery catheter 4, where the tip is placed through a cell of the tubular mesh structure 2 and the expandable sponge structure 1 is being deployed into the aneurysm sac. It is important that the tip of the delivery catheter is through a cell of the tubular mesh structure into the aneurysm because the expandable sponge will expand very quickly after being exposed to the blood and being unconstrained by a catheter. FIG. 6 shows a method of ensuring that the delivery catheter's 4 tip stays inside the aneurysm sac by having a balloon 6 on the tip of it, and when inflated after the tip is within the aneurysm sac it will prevent the catheter tip from backing out of the aneurysm sac. FIG. 7A shows an expandable basket-like structure 7 and FIG. 7B shows an expandable braid-like structure 6 which are alternatives to having a balloon 6 on the tip of the catheter 4.


The expandable tubular mesh structure 2 can be made of a metal or of a polymer. The versions made of a metal can be self-expanding from a smaller compressed state or balloon expandable from a smaller compressed or as-cut state. The self-expanding version may be made of metals which exhibit large amounts of elasticity (i.e. nickel-titanium, spring steel, MP-35N and elgiloy) such that when they are compressed down from their expanded state to the compressed state to load into a delivery catheter, they will substantially return to their expanded condition when released from the catheter. Alternatively, shape memory metals like nickel-titanium can be used to provide large expansion ratios. The balloon expandable version may be made of metals which exhibit large permanent deformations without significantly compromising the mechanical performance. The following are some common medical grade metals which are well suited for this purpose: stainless steel, titanium, tantulum, and martensitic nickel titanium. In either the self-expanding or the balloon expandable case, the intent is to deliver the expandable tubular mesh 2 to the target site in a smaller or compressed condition via a catheter-based delivery system so that the target site can be accessed through a remote vascular access point which is conducive to a percutaneous or minimally invasive approach.


The expandable tubular mesh structure 2 shown in FIGS. 1A, 1B, 1C, 5, and 6 represent a generic, mesh structure. FIG. 8 shows an expandable tubular mesh structure where long continuous struts 9 are connected to anchoring end members 10. This allows the structure to be very low in profile in the compressed state, and the durability of this type of structure can be optimized because no radial element exists in the longitudinal struts 9. FIG. 9 show an alternate expandable tubular mesh structure preferably made from a polymer such as PTFE, Polyester, Polyurethane, and the like. The structure has relatively large holes 11 to give access to the expandable sponge delivery catheter. The ends incorporate an anchoring member 12, either self-expanding or balloon expandable.



FIG. 10 shows a delivery catheter 4 which has been tracked over a guidewire 14, which has been placed into the aneurysm sac through an opening 15 of an existing endoluminal stent-graft 13 which developed a leak. The balloon 6 on the delivery catheter 4 was inflated after the delivery catheter 4 was positioned within the aneurysm sac. FIG. 11 shows the guidewire 14 removed, and the expandable sponge structure 1 being delivered through the delivery catheter 4.



FIG. 12 shows a section view of a tubular balloon graft 19 positioned across an infra-renal aortic aneurysm blocking off the flow to the aneurysm sac. The tubular balloon graft's 19 wall is made of an inner wall 16, an outer wall 17 and a chamber 18 between them. The chamber 18 can be filled with various materials to dictate the mechanical properties of the prosthesis. FIG. 13 shows a bifurcated tubular balloon graft 20 positioned across an infra-renal aortic aneurysm with bi-lateral iliac involvement.


The tubular balloon implant can be made of the various biocompatible materials used to make balloon catheters. Those materials include P.E.T. (Polyester), nylon, urethane, and silicone. It can also be made of other implant grade materials such as ePTFE. One method of making such a device is to start with two thin walled tubes of differing diameters. The difference between the diameters of the tubes will dictate the volume of the balloon chamber. The ends of the tubes can be sealed together with adhesive or by heat to form the balloon chamber. A communication port will be necessary to be able to fill the port with the injected material.


The injected material can be an epoxy, a UV-curable epoxy, silicone, urethane or other type of biocompatible materials such as albumin, collagen, and gelatin glue which is injected into the balloon, and then cured in situ. Or, the injected material doesn't necessarily have to be cured. The as-delivered state may provide the appropriate mechanical properties for the application. Therefore, substances like sterile saline, biocompatible oils, or biocompatible adhesives can be left in the tubular balloon in the as-delivered state.


The tubular balloon graft can be non-porous to very porous. FIG. 14 shows a version where the tubular balloon graft has a porous outer wall 24. The chamber 21 of the tubular balloon graft can be used to deliver an aneurysm sac filling substance such as UV curable adhesive 22. The holes 23 which dictate the porosity of the tubular balloon graft can be created with laser drilling, etching, and other methods. The porosity can be varied in select areas of the graft. FIG. 15 shows a tubular balloon graft with only the ends of the graft have porosity to either promote cellular in-growth or to inject an adhesive which allows secure attachment of the graft ends to the vessel wall.



FIG. 16 shows a tubular balloon graft 19 which is being expanded from a folded condition (not shown) by a balloon catheter 25. Once expanded, the chamber 18 of the tubular balloon graft 19 can be filled with the desired substance through the chamber access port 26. FIG. 17 shows a tubular balloon graft 19 being expanded by an inflation process or filling the chamber 18 of the tubular balloon graft 19 through the chamber access port 26.



FIG. 18 shows a version of the tubular balloon graft with an outer wall 17 which is substantially bulged out so that it fills some or all of the aneurysm sac. FIG. 19 shows a vascular graft 27 which has an integrated balloon 28 attached to the outside surface of the graft. The balloon can be pre-bulged and folded down for delivery, or it can be a very compliant material like silicone, urethane, or latex so that it has no folds whether compressed or expanded. FIG. 20A shows the same type of implant, a graft 27 with an external balloon 28, used in a cerebral vessel aneurysm 29. FIG. 20B show the same implant as 20A, except that the implant balloon does not fully till the aneurysm, which can be acceptable because the graft 27 excludes the aneurysm from the blood flow, and the primary purpose of the balloon 28 is to prevent migration of the graft 27.


The graft 27 can be made of commonly used implant polymers such as PTFE, Polyester, Polyurethane, etc. The balloon 28 surrounding the graft can be made of the same commonly used vascular implant materials as well. The graft and balloon materials can be different, but it is commonly known that using the same material for both would facilitate processing/manufacturing. The theory is that the balloon 28 would preferentially only deploy into the aneurysm sac were the resistance to expansion is minimal as compared to the vessel wall. The graft 27 would provide the primary barrier between the pressurized blood and the thin wall of the aneurysm. Secondarily, the balloon itself provides a buffer from the pressurized blood. The balloon's 28 primary function, however, is to hold the graft 27 in place. Since the expanded section of the implant is “locked” into the aneurysm, the graft 27 should not migrate. Also, the balloon 28, in the filled state, will provide hoop strength to the graft 27.



FIGS. 21A-21E demonstrate one method of delivering a graft with an external balloon to the target site. FIG. 21A shows the implant loaded onto a balloon delivery catheter 30 with an outer sheath 32 and positioned over a guide wire 31 at the aneurysm target site. FIG. 21B shows that once in position, the outer sheath 32 is withdrawn. FIG. 21C shows the balloon delivery catheter 33 being inflated, pushing the implant 34 against the healthy vessel walls on both sides of the aneurysm. FIG. 21D shows that the balloon delivery catheter 30 may also have an implant balloon inflation port 35 which can now be used to fill up the implant balloon 28 with a biocompatible substance. The substance can be sterile saline, contrast agent, hydrogel, and UV cure adhesive to name a few. Most likely, low inflation pressures would be used to fill the implant balloon 28. FIG. 21E shows that once the implant balloon 28 is filled, the implant balloon inflation port 35 can be detached and the delivery catheter 30 removed.

Claims
  • 1. A system for treating an aneurysm comprising: a catheter delivery system having a distal tip, wherein when the catheter delivery system is in a deployed configuration, the distal tip of the catheter delivery system is placed between an outside surface of a stent and a luminal wall of the aneurysm; andan aneurysm filler,wherein the aneurysm filler is passable through the distal tip of the catheter delivery system such that the aneurysm filler, when in a first deployed configuration, deploys through the distal tip between the outside surface of the stent and the luminal wall,wherein when the aneurysm filler is in a second deployed configuration, a portion of the aneurysm filler contacts the stent and the luminal wall,wherein the aneurysm filler forms into a foam configuration when exposed to a fluid,wherein when the aneurysm filler is in the first deployed configuration, the aneurysm filler has a first length, wherein when the aneurysm filler is in the second deployed configuration, the aneurysm filler has a second length, wherein the second length is greater than the first length, and wherein the second length has more bends than the first length.
  • 2. The system of claim 1, wherein the stent bifurcates at a bifurcation point, wherein when the catheter delivery system is in the deployed configuration, the distal tip of the catheter delivery system is superior to the bifurcation point,wherein the aneurysm filler is deployable through the catheter delivery system such that the aneurysm filler exits the catheter delivery system in a direction parallel to a length of a longitudinal axis of the catheter delivery system,wherein the aneurysm filler expands into an expanded configuration when exposed to the fluid, andwherein the fluid is blood.
  • 3. The system of claim 1, wherein the stent bifurcates at a bifurcation point.
  • 4. The system of claim 3, wherein the distal tip of the catheter delivery system is superior to the bifurcation point when the catheter delivery system is in the deployed configuration.
  • 5. The system of claim 1, wherein the aneurysm filler is deployable through the catheter delivery system such that the aneurysm filler exits the catheter delivery system in a direction parallel to a length of a longitudinal axis of the catheter delivery system.
  • 6. The system of claim 1, wherein the aneurysm filler expands into an expanded configuration when exposed to the fluid.
  • 7. The system of claim 1, wherein the fluid is blood.
  • 8. The system of claim 1, wherein the aneurysm filler is porous.
  • 9. The system of claim 1, wherein when the aneurysm filler is in the second deployed configuration, the aneurysm filler coils in the aneurysm.
  • 10. The system of claim 1, wherein the aneurysm filler is expandable to a size greater than an open cell of the stent.
  • 11. The system of claim 1, wherein the aneurysm filler is a polymer.
  • 12. The system of claim 1, wherein when the aneurysm filler is in the second deployed configuration, the aneurysm filler has a fold.
  • 13. A system for treating an aneurysm comprising: a catheter having a distal end, wherein when the catheter is in a deployed configuration, the distal end of the catheter is placed within the aneurysm between an outer surface of a stent and a luminal wall of the aneurysm;an aneurysm filler; andan outer skin,wherein the aneurysm filler is passable through s the distal end of the catheter in a direction parallel to a length of a longitudinal axis of the catheter,wherein when the aneurysm filler is in a deployed configuration, a portion of the aneurysm filler is between the stent and the outer skin,wherein the aneurysm filler forms into an expanded foam configuration when exposed to blood,wherein when the aneurysm filler expands into the expanded foam configuration, the aneurysm filler is larger than an open cell of the stent,wherein the stent is configured to bifurcate at a bifurcation point,wherein the distal end of the catheter is superior to the bifurcation point when the catheter is in the deployed configuration,wherein when the aneurysm filler is in the deployed configuration, the aneurysm filler is a continuous foam structure, andwherein when the aneurysm filler is in the deployed configuration, the continuous foam structure is foldable between the outside surface of the stent and the luminal wall of the aneurysm.
  • 14. The system of claim 13, wherein the aneurysm filler is a polymer.
  • 15. The system of claim 13, wherein when the aneurysm filler is in the expanded foam configuration, the aneurysm filler is porous.
  • 16. The system of claim 13, wherein, when the aneurysm filler is in the deployed configuration, the aneurysm filler coils between the outer surface of the stent and the luminal wall.
  • 17. A method for treating an aneurysm comprising: placing a distal end of a catheter delivery system within the aneurysm between an outer surface of a stent and a luminal wall of the aneurysm; andintroducing an aneurysm filler and an outer skin,wherein the aneurysm filler is passable through the distal end of the catheter delivery system such that the aneurysm filler exits the distal end between the outer surface of the stent and the luminal wall,wherein the aneurysm filler has a first deployed configuration and a second deployed configuration,wherein when the aneurysm filler is in the second deployed configuration, a first side of the outer skin contacts the aneurysm filler and a second side of the outer skin contacts the luminal wall,wherein the aneurysm filler forms into an expanded foam configuration when exposed to a fluid,wherein when the aneurysm filler is in the first deployed configuration, the aneurysm filler has a first length, wherein when the aneurysm filler is in the second deployed configuration, the aneurysm filler has a second length, and wherein the second length has more bends than the first length.
  • 18. The method of claim 17, wherein the aneurysm filler is a polymer, wherein the aneurysm filler exits the distal end of the catheter delivery system in a direction parallel to a length of a longitudinal axis of the catheter delivery system,wherein the aneurysm filling in the expanded foam configuration is larger than an open cell of the stent,wherein the fluid is blood,wherein the stent bifurcates at a bifurcation point, andwherein the distal end of the catheter delivery system is superior to the bifurcation point when the catheter delivery system is in a deployed configuration.
  • 19. The method of claim 17, wherein when the aneurysm filler is in the second deployed configuration, the outer skin is in conformal contact with a wall of the aneurysm.
  • 20. The method of claim 17, wherein, when the aneurysm filler is in the second deployed configuration, the aneurysm filler is fully confined within the aneurysm.
  • 21. The method of claim 17, wherein the aneurysm filler coils in the aneurysm.
CROSS-REFERENCE TO RELATED APPLICATION

This application is a continuation of U.S. patent application Ser. No. 14/225,730, filed Mar. 26, 2014, which is a continuation of U.S. patent application Ser. No. 14/087,980, filed Nov. 22, 2013, (now U.S. Pat. No. 8,936,633 issued Jan. 20, 2015), which is a continuation and claims the benefit of U.S. patent application Ser. No. 13/663,272, filed Oct. 29, 2012, (now U.S. Pat. No. 8,647,377 issued Feb. 11, 2014), which is a continuation of U.S. patent application Ser. No. 13/533,658, filed Jun. 26, 2012, (now U.S. Pat. No. 8,535,367 issued Sep. 17, 2013) which is a continuation of U.S. patent application Ser. No. 11/552,913, filed Oct. 25, 2006, (now U.S. Pat. No. 8,231,665 issued Jul. 31, 2012), which is a continuation of U.S. patent application Ser. No. 10/301,061, filed Nov. 20, 2002, now abandoned, which claims the benefit of U.S. Provisional Application No. 60/333,373, filed Nov. 26, 2001, which are all incorporated herein by reference in their entireties.

US Referenced Citations (259)
Number Name Date Kind
2903365 O'Brian et al. Sep 1959 A
4085757 Pevsner Apr 1978 A
4108173 Silvenko Aug 1978 A
4301803 Handa et al. Nov 1981 A
4341218 U Jul 1982 A
4346712 Handa et al. Aug 1982 A
4553545 Maass et al. Nov 1985 A
4577631 Kreamer Mar 1986 A
4638803 Rand Jan 1987 A
4641653 Rockey Feb 1987 A
4728328 Hughes et al. Mar 1988 A
4944745 Sogard et al. Jul 1990 A
4994069 Ritchart et al. Feb 1991 A
5078726 Kreamer Jan 1992 A
5104404 Wolff Apr 1992 A
5133731 Butler et al. Jul 1992 A
5151105 Kwan-Gett Sep 1992 A
5156620 Pigott Oct 1992 A
5163953 Vince Nov 1992 A
5192301 Kamiya et al. Mar 1993 A
5226911 Chee et al. Jul 1993 A
5282824 Gianturco Feb 1994 A
5308356 Blackshear, Jr. et al. May 1994 A
5312415 Palermo May 1994 A
5330528 Lazim Jul 1994 A
5334217 Das Aug 1994 A
5360443 Barone et al. Nov 1994 A
5395333 Brill Mar 1995 A
5411550 Herweck et al. May 1995 A
5478309 Sweezer et al. Dec 1995 A
5530528 Houki et al. Jun 1996 A
5534024 Rogers et al. Jul 1996 A
5540711 Kieturakis et al. Jul 1996 A
5558642 Schweich, Jr. et al. Sep 1996 A
5575817 Martin Nov 1996 A
5578071 Parodi Nov 1996 A
5582619 Ken Dec 1996 A
5591195 Taheri et al. Jan 1997 A
5593442 Klein Jan 1997 A
5613981 Boyle et al. Mar 1997 A
5628783 Quiachon et al. May 1997 A
5665117 Rhodes Sep 1997 A
5667767 Greff et al. Sep 1997 A
5693088 Lazarus Dec 1997 A
5702361 Evans et al. Dec 1997 A
5704910 Humes Jan 1998 A
5713917 Leonhardt et al. Feb 1998 A
5725568 Hastings Mar 1998 A
5728131 Frantzen et al. Mar 1998 A
5749894 Engelson May 1998 A
5752974 Rhee et al. May 1998 A
5766160 Samson et al. Jun 1998 A
5769882 Fogarty et al. Jun 1998 A
5785679 Abolfathi et al. Jul 1998 A
5795331 Cragg et al. Aug 1998 A
5800526 Anderson et al. Sep 1998 A
5823198 Jones et al. Oct 1998 A
5824037 Fogarty et al. Oct 1998 A
5824040 Cox et al. Oct 1998 A
5830230 Berryman et al. Nov 1998 A
5843160 Rhodes Dec 1998 A
5861003 Latson et al. Jan 1999 A
5876448 Thompson et al. Mar 1999 A
5916235 Guglielmi Jun 1999 A
5925059 Palermo et al. Jul 1999 A
5928260 Chin et al. Jul 1999 A
5935145 Villar et al. Aug 1999 A
5944733 Engelson Aug 1999 A
5951599 McCrory Sep 1999 A
5980514 Kupiecki et al. Nov 1999 A
5984963 Ryan et al. Nov 1999 A
5994750 Yagi Nov 1999 A
6015424 Rosenbluth et al. Jan 2000 A
6015431 Thornton et al. Jan 2000 A
6024754 Engelson Feb 2000 A
6059823 Holman et al. May 2000 A
6063121 Xavier et al. May 2000 A
6066149 Samson et al. May 2000 A
6080194 Pachence et al. Jun 2000 A
6093199 Brown et al. Jul 2000 A
6096021 Helm et al. Aug 2000 A
6102940 Robichon et al. Aug 2000 A
6110198 Fogarty et al. Aug 2000 A
6113629 Ken Sep 2000 A
6136015 Kurz et al. Oct 2000 A
6139520 McCrory et al. Oct 2000 A
6146373 Cragg et al. Nov 2000 A
6149664 Kurz Nov 2000 A
6152956 Pierce Nov 2000 A
6165193 Greene, Jr. et al. Dec 2000 A
6165194 Denardo Dec 2000 A
6168592 Kupiecki et al. Jan 2001 B1
6190402 Horton et al. Feb 2001 B1
6193745 Fogarty et al. Feb 2001 B1
6196230 Hall et al. Mar 2001 B1
6203550 Olson Mar 2001 B1
6203779 Ricci et al. Mar 2001 B1
6214036 Letendre et al. Apr 2001 B1
6231562 Khosravi et al. May 2001 B1
6238403 Greene, Jr. et al. May 2001 B1
6248122 Klumb et al. Jun 2001 B1
6261305 Marotta et al. Jul 2001 B1
6273909 Kugler et al. Aug 2001 B1
6273917 Inoue Aug 2001 B1
6283991 Cox et al. Sep 2001 B1
6287315 Wijeratne et al. Sep 2001 B1
6287335 Drasler et al. Sep 2001 B1
6290731 Solovay et al. Sep 2001 B1
6293960 Ken Sep 2001 B1
6296603 Turnlund et al. Oct 2001 B1
6296604 Garibaldi et al. Oct 2001 B1
6299597 Buscemi et al. Oct 2001 B1
6299619 Greene, Jr. et al. Oct 2001 B1
6312421 Boock Nov 2001 B1
6312462 McDermott et al. Nov 2001 B1
6312463 Rourke et al. Nov 2001 B1
6315709 Garibaldi et al. Nov 2001 B1
6319276 Holman et al. Nov 2001 B1
6325819 Pavcnik et al. Dec 2001 B1
6331184 Abrams Dec 2001 B1
6334869 Leonhardt et al. Jan 2002 B1
6344041 Kupiecki et al. Feb 2002 B1
6344048 Chin et al. Feb 2002 B1
6344056 Dehdashtian Feb 2002 B1
6350270 Roue Feb 2002 B1
6358556 Ding et al. Mar 2002 B1
6361556 Chuter Mar 2002 B1
6364823 Garibaldi et al. Apr 2002 B1
6375668 Gifford et al. Apr 2002 B1
6375669 Rosenbluth et al. Apr 2002 B1
6379329 Naglreiter et al. Apr 2002 B1
6383174 Eder May 2002 B1
6395019 Chobotov May 2002 B2
6409757 Trout, III et al. Jun 2002 B1
6458119 Berenstein et al. Oct 2002 B1
6463317 Kucharczyk et al. Oct 2002 B1
6485510 Camrud et al. Nov 2002 B1
6494889 Fleischman et al. Dec 2002 B1
6506204 Mazzocchi Jan 2003 B2
6511468 Cragg et al. Jan 2003 B1
6521244 Kanesaka Feb 2003 B1
6527739 Bigus et al. Mar 2003 B1
6544219 Happ et al. Apr 2003 B2
6544276 Azizi Apr 2003 B1
6551280 Knighton et al. Apr 2003 B1
6551303 Van Tassel et al. Apr 2003 B1
6558367 Cragg et al. May 2003 B1
6565602 Rolando et al. May 2003 B2
6585756 Strecker Jul 2003 B1
6585760 Fogarty Jul 2003 B1
6589265 Palmer et al. Jul 2003 B1
6592614 Lenker et al. Jul 2003 B2
6613037 Khosravi et al. Sep 2003 B2
6613074 Mitelberg et al. Sep 2003 B1
6616684 Vidlund et al. Sep 2003 B1
6626928 Raymond et al. Sep 2003 B1
6626938 Butaric et al. Sep 2003 B1
6629947 Sahatjian et al. Oct 2003 B1
6645167 Whalen, II et al. Nov 2003 B1
6656214 Fogarty et al. Dec 2003 B1
6663607 Slaikeu et al. Dec 2003 B2
6663667 Dehdashtian et al. Dec 2003 B2
6692510 West Feb 2004 B2
6695876 Marotta et al. Feb 2004 B1
6712826 Lui Mar 2004 B2
6723108 Jones et al. Apr 2004 B1
6729356 Baker et al. May 2004 B1
6730119 Smalling May 2004 B1
6764510 Vidlund et al. Jul 2004 B2
6827735 Greenberg Dec 2004 B2
6843803 Ryan et al. Jan 2005 B2
6852097 Fulton, III Feb 2005 B1
6921410 Porter Jul 2005 B2
7070609 West Jul 2006 B2
7070616 Majercak et al. Jul 2006 B2
7081129 Chobotov Jul 2006 B2
7101396 Artof et al. Sep 2006 B2
7128736 Abrams et al. Oct 2006 B1
7147660 Chobotov et al. Dec 2006 B2
7147661 Chobotov et al. Dec 2006 B2
7530988 Evans et al. May 2009 B2
7615071 Chobotov Nov 2009 B2
7708771 Chuter et al. May 2010 B2
8231665 Kim et al. Jul 2012 B2
8231666 Kim et al. Jul 2012 B2
8262686 Fogarty et al. Sep 2012 B2
8361136 Chobotov Jan 2013 B2
8535367 Kim et al. Sep 2013 B2
8562662 Kim et al. Oct 2013 B2
8647377 Kim et al. Feb 2014 B2
8801769 Chobotov Aug 2014 B2
8936633 Kim et al. Jan 2015 B2
9295569 Kim et al. Mar 2016 B2
9561037 Fogarty et al. Feb 2017 B2
9561096 Kim et al. Feb 2017 B2
9561097 Kim et al. Feb 2017 B1
9615912 Fogarty et al. Apr 2017 B2
9629636 Fogarty et al. Apr 2017 B2
9750504 Fogarty et al. Sep 2017 B2
9913651 Fogarty et al. Mar 2018 B2
20010020184 Dehdashtian et al. Sep 2001 A1
20010044621 Klumb et al. Nov 2001 A1
20010047202 Slaikeu et al. Nov 2001 A1
20020019665 Dehdashtian et al. Feb 2002 A1
20020026217 Baker et al. Feb 2002 A1
20020045848 Jaafar et al. Apr 2002 A1
20020052643 Wholey et al. May 2002 A1
20020058986 Landau et al. May 2002 A1
20020065542 Lax et al. May 2002 A1
20020077693 Barclay et al. Jun 2002 A1
20020082638 Porter et al. Jun 2002 A1
20020082682 Barclay et al. Jun 2002 A1
20020099441 Dehdashtian Jul 2002 A1
20020107565 Greenhalgh Aug 2002 A1
20020151957 Kerr Oct 2002 A1
20020169497 Wholey et al. Nov 2002 A1
20020183841 Cohn et al. Dec 2002 A1
20020193821 Trout Dec 2002 A1
20030004531 Jones et al. Jan 2003 A1
20030014075 Rosenbluth et al. Jan 2003 A1
20030028209 Teoh et al. Feb 2003 A1
20030051735 Pavcnik et al. Mar 2003 A1
20030074017 Shah Apr 2003 A1
20030130724 DePalma et al. Jul 2003 A1
20030171805 Berg et al. Sep 2003 A1
20030195607 Trout et al. Oct 2003 A1
20030204246 Chu et al. Oct 2003 A1
20030216802 Chobotov Nov 2003 A1
20030220666 Mirigian et al. Nov 2003 A1
20030220667 van der Burg et al. Nov 2003 A1
20030229286 Lenker Dec 2003 A1
20040044358 Khosravi et al. Mar 2004 A1
20040044361 Frazier et al. Mar 2004 A1
20040073190 Deem et al. Apr 2004 A1
20040073288 Kerr Apr 2004 A1
20040098027 Teoh et al. May 2004 A1
20040116997 Taylor et al. Jun 2004 A1
20040186556 Hogendijk et al. Sep 2004 A1
20040210249 Fogarty et al. Oct 2004 A1
20040254625 Stephens et al. Dec 2004 A1
20050249776 Chen et al. Nov 2005 A1
20060292206 Kim et al. Dec 2006 A1
20070050008 Kim et al. Mar 2007 A1
20070055355 Kim et al. Mar 2007 A1
20070061005 Kim et al. Mar 2007 A1
20080275536 Zarins et al. Nov 2008 A1
20120179192 Fogarty et al. Jul 2012 A1
20120265287 Sharma et al. Oct 2012 A1
20120330343 Kim et al. Dec 2012 A1
20130060320 Fogarty et al. Mar 2013 A1
20140081374 Kim et al. Mar 2014 A1
20140088690 Fogarty et al. Mar 2014 A1
20140142685 Kim et al. May 2014 A1
20170020653 Kim et al. Jan 2017 A1
20170020654 Fogarty et al. Jan 2017 A1
20170086853 Fogarty et al. Mar 2017 A1
20170333047 Fogarty et al. Nov 2017 A1
20170360553 Fogarty et al. Dec 2017 A1
20180199946 Fogarty et al. Jul 2018 A1
Foreign Referenced Citations (11)
Number Date Country
2003204493 Dec 2003 AU
2689388 Jul 1999 FR
WO 1999016384 Apr 1999 WO
WO 1999043273 Sep 1999 WO
WO 1999065418 Dec 1999 WO
WO 2000069367 Nov 2000 WO
WO 2001006950 Feb 2001 WO
WO 2001028434 Apr 2001 WO
WO 2001093920 Dec 2001 WO
WO 2002102282 Dec 2002 WO
WO 2004045393 Jun 2004 WO
Non-Patent Literature Citations (15)
Entry
Franklin et al, “Uptake of Tetracycline by Aortic Aneurysm Wall and Its Effect on Inflammation and Proteolysis,” Brit. J. Surgery, 86(6):771-775, 1999.
Pyo et al., “Targeted Gene Disruption of Matrix Metalloproteinase-9 (Gelatinase B) Suppresses Development of Experimental Abdominal Aortic Aneurysms,” J. Clinical Investigation, 105(11):1641-1649, 2000.
Tambiah et al, “Provocation of Experimental Aortic Inflammation Mediators and Chlamydia Pneumoniae,” Brit. J. Surgery, 88(7):935-940, 2001.
Villareal et al, “Early Results Using Bare Metal Stents With or Without Coil Embolization for AAA Exclusion,” Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists, 8 pages, 2001.
Walton, et al, “Inhibition of Prostoglandin E2 Synthesis in Abdominal Aortic Aneurysms,” Circulation, pp. 48-54, Jul. 6, 1999.
Xu et al, “Sp 1 Increases Expression of Cyclooxygenase-2 in Hypoxic Vascular Endothelium,” J. Biological Chemistry, 275(32):24583-24589, 2000.
U.S. Appl. No. 10/301,061, filed Nov. 20, 2002.
U.S. Appl. No. 11/555,938, filed Nov. 2, 2006.
U.S. Appl. No. 11/552,913, filed Oct. 25, 2006.
U.S. Appl. No. 11/552,925, filed Oct. 25, 2006.
U.S. Appl. No. 13/533,658, filed Jun. 26, 2012.
U.S. Appl. No. 13/663,272, filed Oct. 29, 2012.
U.S. Appl. No. 14/087,980, filed Nov. 22, 2013.
U.S. Appl. No. 14/165,140, filed Jan. 27, 2014.
U.S. Appl. No. 14/225,730, filed Mar. 26, 2014.
Related Publications (1)
Number Date Country
20160113659 A1 Apr 2016 US
Provisional Applications (1)
Number Date Country
60333373 Nov 2001 US
Continuations (6)
Number Date Country
Parent 14225730 Mar 2014 US
Child 14990698 US
Parent 14087980 Nov 2013 US
Child 14225730 US
Parent 13663272 Oct 2012 US
Child 14087980 US
Parent 13533658 Jun 2012 US
Child 13663272 US
Parent 11552913 Oct 2006 US
Child 13533658 US
Parent 10301061 Nov 2002 US
Child 11552913 US